Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis.

Hissink Muller PCE, van Braak WG, Schreurs D, Nusman CM, Bergstra SA, Hemke R, Schonenberg-Meinema D, van den Berg JM, Kuijpers TW, Koopman-Keemink Y, van Rossum MAJ, van Suijlekom-Smit LWA, Brinkman DMC, Allaart CF, Ten Cate R, Maas M.

Pediatr Rheumatol Online J. 2019 Sep 4;17(1):62. doi: 10.1186/s12969-019-0362-1.

2.

Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?

Hissink Muller PCE, Yildiz B, Allaart CF, Brinkman DMC, van Rossum M, van Suijlekom-Smit LWA, van den Berg JM, Ten Cate R, de Vries MC.

BMC Med Ethics. 2018 Dec 20;19(1):96. doi: 10.1186/s12910-018-0336-8.

3.

Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.

Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, Bekkering PW, Kuijpers TW, Van Rossum M, van Suijlekom-Smit LWA, van den Berg JM, Boehringer S, Allaart CF, Ten Cate R.

Ann Rheum Dis. 2019 Jan;78(1):51-59. doi: 10.1136/annrheumdis-2018-213902. Epub 2018 Oct 11.

PMID:
30309970
4.

S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.

Gohar F, Anink J, Moncrieffe H, Van Suijlekom-Smit LWA, Prince FHM, van Rossum MAJ, Dolman KM, Hoppenreijs EPAH, Ten Cate R, Ursu S, Wedderburn LR, Horneff G, Frosch M, Foell D, Holzinger D.

J Rheumatol. 2018 Apr;45(4):547-554. doi: 10.3899/jrheum.170438. Epub 2018 Jan 15.

5.

Manipulative interventions for reducing pulled elbow in young children.

Krul M, van der Wouden JC, Kruithof EJ, van Suijlekom-Smit LW, Koes BW.

Cochrane Database Syst Rev. 2017 Jul 28;7:CD007759. doi: 10.1002/14651858.CD007759.pub4. Review.

6.

Interventions for cutaneous molluscum contagiosum.

van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van Suijlekom-Smit LW, Koning S.

Cochrane Database Syst Rev. 2017 May 17;5:CD004767. doi: 10.1002/14651858.CD004767.pub4. Review.

7.

A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.

Hissink Muller PC, Brinkman DM, Schonenberg D, Koopman-Keemink Y, Brederije IC, Bekkering WP, Kuijpers TW, van Rossum MA, van Suijlekom-Smit LW, van den Berg JM, Allaart CF, Ten Cate R.

Pediatr Rheumatol Online J. 2017 Feb 6;15(1):11. doi: 10.1186/s12969-017-0138-4.

8.

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.

Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, Hoppenreijs EP, ten Cate R, Ursu S, Wedderburn LR, Horneff G, Frosch M, Vogl T, Gohar F, Foell D, Roth J, Holzinger D.

Arthritis Res Ther. 2015 Aug 7;17:200. doi: 10.1186/s13075-015-0723-1.

9.

Bone health of patients with juvenile idiopathic arthritis: a comparison between dual-energy X-ray absorptiometry and digital X-ray radiogrammetry.

Nusman CM, Anink J, Otten MH, van Rossum MA, van Rijn RR, Maas M, van Suijlekom-Smit LW.

Eur J Radiol. 2015 Oct;84(10):1999-2003. doi: 10.1016/j.ejrad.2015.06.015. Epub 2015 Jun 19.

PMID:
26116967
10.

Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.

Anink J, Prince FH, Dijkstra M, Otten MH, Twilt M, ten Cate R, Gorter SL, Koopman-Keemink Y, van Rossum MA, Hoppenreijs EP, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2015 Nov;54(11):1964-9. doi: 10.1093/rheumatology/kev195. Epub 2015 Jun 14.

PMID:
26078219
11.

Patient-reported joint count in juvenile idiopathic arthritis: the reliability of a manikin format.

Dijkstra ME, Anink J, van Pelt PA, Hazes JM, van Suijlekom-Smit LW.

J Rheumatol. 2015 Mar;42(3):527-33. doi: 10.3899/jrheum.140073. Epub 2014 Nov 29.

PMID:
25433530
12.

Automated determination of bone age and bone mineral density in patients with juvenile idiopathic arthritis: a feasibility study.

Anink J, Nusman CM, van Suijlekom-Smit LW, van Rijn RR, Maas M, van Rossum MA.

Arthritis Res Ther. 2014 Aug 27;16(4):424. doi: 10.1186/s13075-014-0424-1.

13.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.

PMID:
24641940
14.

Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients.

Muller PC, Anink J, Shi J, Levarht EW, Reinards TH, Otten MH, van Tol MJ, Jol-van der Zijde CM, Brinkman DM, Allaart CF, Hoppenreijs EP, Koopman-Keemink Y, Kamphuis SS, Dolman K, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW, Schilham MW, Huizinga TW, Toes RE, Ten Cate R, Trouw LA.

Ann Rheum Dis. 2013 Dec;72(12):2053-5. doi: 10.1136/annrheumdis-2013-203650. Epub 2013 Jul 19. No abstract available.

PMID:
23873877
15.

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Sep;52(9):1674-9. doi: 10.1093/rheumatology/ket170. Epub 2013 Jun 4.

PMID:
23740187
16.

Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.

Prince FH, van Suijlekom-Smit LW.

Paediatr Drugs. 2013 Aug;15(4):271-80. doi: 10.1007/s40272-013-0023-7.

PMID:
23606042
17.

Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.

Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Apr;52(4):712-7. doi: 10.1093/rheumatology/kes373. Epub 2012 Dec 24.

PMID:
23267169
18.

Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.

Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW.

Ann Rheum Dis. 2013 Nov;72(11):1806-12. doi: 10.1136/annrheumdis-2012-201991. Epub 2012 Nov 21. Review.

PMID:
23172748
19.

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.

Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

Ann Rheum Dis. 2013 May;72(5):721-7. doi: 10.1136/annrheumdis-2011-201060. Epub 2012 Jun 23.

PMID:
22730374
20.

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.

Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, ten Cate R, Hoppenreijs EP, Hansmann S, Moncrieffe H, Ursu S, Wedderburn LR, Roth J, Foell D, Wittkowski H.

Ann Rheum Dis. 2012 Jun;71(6):974-80. doi: 10.1136/annrheumdis-2011-200598. Epub 2012 Jan 20.

PMID:
22267331
21.

Manipulative interventions for reducing pulled elbow in young children.

Krul M, van der Wouden JC, van Suijlekom-Smit LW, Koes BW.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007759. doi: 10.1002/14651858.CD007759.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jul 28;7:CD007759.

22.

Interventions for impetigo.

Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, Berger M, van der Wouden JC.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD003261. doi: 10.1002/14651858.CD003261.pub3. Review.

PMID:
22258953
23.

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

JAMA. 2011 Dec 7;306(21):2340-7. doi: 10.1001/jama.2011.1671. Epub 2011 Nov 6.

PMID:
22056397
24.

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.

J Rheumatol. 2011 Oct;38(10):2258-63. doi: 10.3899/jrheum.110145. Epub 2011 Aug 15.

PMID:
21844151
25.

An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.

Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, Koopman-Keemink Y, Gorter SL, Raat H, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2011 Jun;50(6):1131-6. doi: 10.1093/rheumatology/keq432. Epub 2011 Jan 27.

PMID:
21278067
26.

Asthma prescription patterns for children: can GPs do better?

Uijen JH, van der Wouden JC, Schellevis FG, Willemsen SP, van Suijlekom-Smit LW, Bindels PJ.

Eur J Gen Pract. 2011 Jun;17(2):109-15. doi: 10.3109/13814788.2010.544299. Epub 2010 Dec 29.

PMID:
21190392
27.

Diagnosis and management of juvenile idiopathic arthritis.

Prince FH, Otten MH, van Suijlekom-Smit LW.

BMJ. 2010 Dec 3;341:c6434. doi: 10.1136/bmj.c6434. Review. No abstract available.

PMID:
21131338
28.

Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?

Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP, Koopman-Keemink Y, Oranje AP, de Waard-van der Spek FB, Gorter SL, Armbrust W, Dolman KM, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2011 Feb;70(2):337-40. doi: 10.1136/ard.2010.135731. Epub 2010 Nov 10.

PMID:
21068101
29.

Disease activity patterns in juvenile systemic lupus erythematosus and its relation to early aggressive treatment.

Otten MH, Cransberg K, van Rossum MA, Groothoff JW, Kist-van Holthe JE, Ten Cate R, Van Suijlekom-Smit LW.

Lupus. 2010 Nov;19(13):1550-6. doi: 10.1177/0961203310374485. Epub 2010 Jul 21.

PMID:
20659970
30.

Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis.

Albers HM, Brinkman DM, Kamphuis SS, van Suijlekom-Smit LW, van Rossum MA, Hoppenreijs EP, Girschick HJ, Wouters C, Saurenmann RK, Houwing-Duistermaat JJ, Huizinga TW, Schilham MW, ten Cate R.

Arthritis Care Res (Hoboken). 2010 Feb;62(2):204-12. doi: 10.1002/acr.20069.

31.

Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.

Otten MH, Prince FH, Twilt M, van Rossum MA, Armbrust W, Hoppenreijs EP, Kamphuis S, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Ten Cate R, van Suijlekom-Smit LW.

J Rheumatol. 2010 Mar;37(3):665-7. doi: 10.3899/jrheum.090550. Epub 2010 Jan 15.

PMID:
20080910
32.

Nursemaid's elbow: Its diagnostic clues and preferred means of reduction.

Krul M, van der Wouden JC, Koes BW, Schellevis FG, van Suijlekom-Smit LW.

J Fam Pract. 2010 Jan;59(1):E5-7. Review. No abstract available.

PMID:
20074495
33.

Acute non-traumatic hip pathology in children: incidence and presentation in family practice.

Krul M, van der Wouden JC, Schellevis FG, van Suijlekom-Smit LW, Koes BW.

Fam Pract. 2010 Apr;27(2):166-70. doi: 10.1093/fampra/cmp092. Epub 2009 Dec 21.

PMID:
20026553
34.

Long-term follow-up of craniofacial alterations in juvenile idiopathic arthritis.

Twilt M, Schulten AJ, Prahl-Andersen B, van Suijlekom-Smit LW.

Angle Orthod. 2009 Nov;79(6):1057-62. doi: 10.2319/093008-511R.1.

PMID:
19852594
35.

Manipulative interventions for reducing pulled elbow in young children.

Krul M, van der Wouden JC, van Suijlekom-Smit LW, Koes BW.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007759. doi: 10.1002/14651858.CD007759.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;1:CD007759.

PMID:
19821438
36.

Interventions for cutaneous molluscum contagiosum.

van der Wouden JC, van der Sande R, van Suijlekom-Smit LW, Berger M, Butler CC, Koning S.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004767. doi: 10.1002/14651858.CD004767.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 May 17;5:CD004767.

PMID:
19821333
37.

Musculoskeletal problems in overweight and obese children.

Krul M, van der Wouden JC, Schellevis FG, van Suijlekom-Smit LW, Koes BW.

Ann Fam Med. 2009 Jul-Aug;7(4):352-6. doi: 10.1370/afm.1005.

38.

Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis.

Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, Cate RT, Koopman-Keemink Y, van Santen-Hoeufft M, Raat H, van Suijlekom-Smit LW.

Ann Rheum Dis. 2010 Jan;69(1):138-42. doi: 10.1136/ard.2009.111260.

PMID:
19581280
39.

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.

Prince FH, Twilt M, Simon SC, van Rossum MA, Armbrust W, Hoppenreijs EP, Kamphuis S, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, ten Cate R, van Suijlekom-Smit LW.

Ann Rheum Dis. 2009 Jul;68(7):1228-9. doi: 10.1136/ard.2008.101030. No abstract available.

PMID:
19525408
40.

Development of a digital Childhood Health Assessment Questionnaire for systematic monitoring of disease activity in daily practice.

Geerdink LM, Prince FH, Looman CW, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2009 Aug;48(8):958-63. doi: 10.1093/rheumatology/kep135. Epub 2009 Jun 9.

PMID:
19509189
41.

Foot problems in children presented to the family physician: a comparison between 1987 and 2001.

Krul M, van der Wouden JC, Schellevis FG, van Suijlekom-Smit LW, Koes BW.

Fam Pract. 2009 Jun;26(3):174-9. doi: 10.1093/fampra/cmp018. Epub 2009 Mar 6.

PMID:
19270034
42.

Development of a web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl.

Prince FH, Ferket IS, Kamphuis S, Armbrust W, Ten Cate R, Hoppenreijs EP, Koopman-Keemink Y, van Rossum MA, van Santen-Hoeufft M, Twilt M, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2008 Sep;47(9):1413-6. doi: 10.1093/rheumatology/ken245. Epub 2008 Jul 16.

PMID:
18632789
43.

Self-reported prevalence of warts in children and GP consultation.

Mohammedamin RS, van der Wouden JC, Koning S, van der Linden MW, Schellevis FG, van Suijlekom-Smit LW, Koes BW.

Eur J Gen Pract. 2008;14(1):34-6. doi: 10.1080/13814780701855716. No abstract available.

PMID:
18464171
44.

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.

Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2009 May;68(5):635-41. doi: 10.1136/ard.2007.087411. Epub 2008 Apr 15.

PMID:
18413443
45.

Long-term followup of temporomandibular joint involvement in juvenile idiopathic arthritis.

Twilt M, Schulten AJ, Verschure F, Wisse L, Prahl-Andersen B, van Suijlekom-Smit LW.

Arthritis Rheum. 2008 Apr 15;59(4):546-52. doi: 10.1002/art.23532.

46.

The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.

Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, Brunner J, Dannecker G, Silva CA, Stanevicha V, Cate RT, van Suijlekom-Smit LW, Voygioyka O, Fischbach M, Foeldvari I, Hilario O, Modesto C, Saurenmann RK, Sauvain MJ, Scheibel I, Sommelet D, Tambic-Bukovac L, Barcellona R, Brik R, Ehl S, Jovanovic M, Rovensky J, Bagnasco F, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Arthritis Rheum. 2008 Jan 15;59(1):4-13. doi: 10.1002/art.23248.

47.

Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis.

Prince FH, van Suijlekom-Smit LW.

Rheumatol Int. 2008 Feb;28(4):397-8, author reply 399. Epub 2007 Oct 17. No abstract available.

PMID:
17940772
48.

Reported incidence and treatment of dermatophytosis in children in general practice: a comparison between 1987 and 2001.

Mohammedamin RS, van der Wouden JC, Koning S, Schellevis FG, van Suijlekom-Smit LW, Koes BW.

Mycopathologia. 2007 Dec;164(6):271-8. Epub 2007 Sep 23.

49.

Incidence of temporomandibular involvement in juvenile idiopathic arthritis.

Twilt M, Arends LR, Cate RT, van Suijlekom-Smit LW.

Scand J Rheumatol. 2007 May-Jun;36(3):184-8.

PMID:
17657671
50.

Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.

van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, ten Cate R, van Suijlekom-Smit LW, Wulffraat NM, van Luijk WH, Oostveen JC, Kuis W, Dijkmans BA; Dutch Juvenile Idiopathic Arthritis Study group.

Ann Rheum Dis. 2007 Nov;66(11):1518-24. Epub 2007 May 9.

Supplemental Content

Loading ...
Support Center